Loading…
Loading…
ARGX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ARGX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ARGX and 80,000+ other tickers.
See exactly how ARGX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ARGX and 80,000+ other tickers.
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous…
Boston Common Asset Management LLC bought a new position in argenex SE (NASDAQ: ARGX) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 3,753 shares of the company's stock, valued at approximately $2,741,000. Other large investors have also recently modified their holdings of
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration agreement with argenx, a leading immunology innovation company. The collaboration will see argenx get access to Chai's AI platform and apply de novo antibody discovery across therapeutic targets. argenx has built one of biotechnology's most productive antibody engines, combining deep immunology expertise with a high-powered antibody engineering tea.
Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?